# US 2023/0056466 A1 · Novel precursor mirna and application thereof in tumor treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056466 A1
- Document ID: US20230056466A1
- Status: Published application
- Kind: A1
- Application number: 17/817,303
- Filed: 2022-08-03
- Published: 2023-02-23
- Earliest claimed: 2014-11-17
- Assignees: Jiangsu Micromedmark Biotech Co., Ltd.
- Applicants: Jiangsu Micromedmark Biotech Co., Ltd.
- Inventors: Chenyu ZHANG; Ke ZENG; Xi CHEN; Junfeng ZHANG; Hongwei LIANG
- Web page: https://patentgrep.com/patent/US20230056466A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/51: Specially adapted vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a precursor miRNA and application thereof in a tumor treatment. The precursor miRNA from the 5′ end to 3′ end has a structure presented as formula I: B1 is anti-miRNA-214-5p; B2 is an essentially complementary sequence or a totally complementary sequence to B1, and B2 and C are not complementary; C is a sequence having a stem-loop structure; A1 and A2 are respectively RNA sequences having no or 4-5 bases freely selected bases respectively; the precursor miRNA shown can be processed to form anti-miRNA-214 in a host, and only anti-miRNA-214-5p but not anti-miRNA-214-3p is expressed in the anti-miRNA-214.

## Claims

### Claim 1

A pharmaceutical preparation, characterised in that the preparation comprises:
(a) an expression vector for expressing anti-miRNAs and/or siRNAs; and
(b) a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

A method for administering a medicament, characterised in that the method comprises the step of:
administering the pharmaceutical preparation of claim 1 at a first site on a mammal, so that the expression vector is processed to form a microvesicle in the mammal which is transported to a second site on the mammal where the anti-miRNAs and/or siRNAs are expressed.

### Claim 3

A precursor sequence, characterised in that the sequence has a structure from the 5′ terminus to the 3′ terminus as shown in formula I:
wherein B1 is a first ribonucleic acid sequence as desired, and comprises an anti-miRNA sequence form or an siRNA sequence form;
B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C;
C is a stem-loop structure sequence; and
A1 and A2 are null or are optionally RNA sequences consisting of 4-5 bases respectively;
wherein the precursor can express (or produce or enrich) the first ribonucleic acid sequence in a host, but cannot express (or produce or enrich) a second ribonucleic acid sequence complementary to the first ribonucleic acid sequence.

### Claim 4 (depends on 3)

The precursor sequence of claim 3, characterised in that the sequence has a structure from the 5′ terminus to the 3′ terminus as shown in formula I:
wherein B1 is anti-miRNA-214-5p;
B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C;
C is a stem-loop structure sequence, preferably a sequence shown as SEQ ID NO.: 1; and
A1 and A2 are null or are optionally RNA sequences consisting of 4-5 bases respectively;
wherein the precursor sequence as shown can be processed in the host to form anti-miRNA-214, and only the anti-miRNA-214-5p, rather than the anti-miRNA-214-3p, in the anti-miRNA-214 is expressed.

### Claim 5 (depends on 4)

The precursor sequence of claim 4, characterised in that substantially complementary means that there are 2-8 non-complementary bases between the B2 and B1, preferably there are 3-5 non-complementary bases between the B2 and B1, and more preferably 1-2 bases are deleted in B2 as compared with B1.

### Claim 6 (depends on 4)

The precursor sequence of claim 4, characterised in that A1 is UGCUG; and/or A2 is CAGG or CAGGA.

### Claim 7 (depends on 4)

A polynucleotide, characterised in that the polynucleotide can be transcribed by a host to form the precursor sequence of claim 4.

### Claim 8 (depends on 4, 7)

An expression vector, characterised in that the expression vector contains the precursor sequence of claim 4 or the polynucleotide of claim 7.

### Claim 9 (depends on 4, 8)

A pharmaceutical composition, characterised in that the pharmaceutical composition comprises the precursor sequence of claim 4 or the expression vector of claim 8, and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 4, 8, 9)

The pharmaceutical composition of claim 9, characterised in that the pharmaceutical composition is the expression vector of claim 8, and preferably is a plasmid containing the precursor sequence of claim 4; and/or
the dosage form of the pharmaceutical composition comprises a tablet, a capsule, a powder, a pill, a granule, a syrup, a solution, a suspension liquid, an emulsion, a suspension, an injection solution, or an injectable powder; preferably the dosage form is an injection, such as an intravenous injection or an intraperitoneal injection.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, characterised in that the administration mode of the pharmaceutical composition comprises oral, respiratory tract, injection, transdermal, mucosal, or cavity administration; preferably the administration mode comprises direct injection of a plasmid.

### Claim 12 (depends on 4, 8)

A use of the precursor sequence of claim 4 or the expression vector of claim 8, characterised in that the use is: (i) for preparing an inhibitor of miRNA-214; and/or (ii) for preparing a pharmaceutical composition against a malignant tumor highly expressing miRNA-214;
preferably, the malignant tumor comprises liver cancer, lung cancer, stomach cancer, oesophageal cancer, ovarian cancer, colorectal cancer, cervical cancer, pancreatic cancer, prostatic cancer, leukaemia or breast cancer.
